These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 6756854)

  • 1. [Buflomedil in arterial occlusive disease. Results of a controlled study].
    Trübestein G; Balzer K; Bisler H; Klüken N; Mahfoud Y; Müller-Wiefel H; Unkel B; Ziegler W
    Dtsch Med Wochenschr; 1982 Dec; 107(51-52):1957-61. PubMed ID: 6756854
    [No Abstract]   [Full Text] [Related]  

  • 2. Buflomedil in arterial occlusive disease: results of a controlled multicenter study.
    Trübestein G; Balzer K; Bisler H; Klüken N; Muller-Wiefel H; Unkel B; Mahfoud Y; Ziegler W
    Angiology; 1984 Aug; 35(8):500-5. PubMed ID: 6383127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness of buflomedil in arterial occlusive disease. Modification of transcutaneous oxygen pressure in a placebo-controlled double-blind study].
    Sunder-Plassmann L; Gandolfo AM; Utz C
    MMW Munch Med Wochenschr; 1984 Mar; 126(9):247-8. PubMed ID: 6425678
    [No Abstract]   [Full Text] [Related]  

  • 4. [Action and tolerability of delayed-action buflomedil in obliterating arteriopathies of the lower limbs. A multicenter study].
    Andreozzi GM; Lepore R
    Clin Ter; 1990 Nov; 135(4):273-81. PubMed ID: 2150026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of long-term safety data with buflomedil.
    Bachand RT; Dubourg AY
    J Int Med Res; 1990; 18(3):245-52. PubMed ID: 2193838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical experience and instrumental evaluation of buflomedil hydrochloride in the therapy of chronic obliterative arteriopathies of the legs].
    Lucisano V; Margheriti R; Matone P; Morrieri C; Rugolo A; Corsi V
    Clin Ter; 1986 Jun; 117(6):499-509. PubMed ID: 3527536
    [No Abstract]   [Full Text] [Related]  

  • 7. Positive effect of oral buflomedil on exercise-induced haemorheological damage and on claudication distance in peripheral obliterative arterial disease patients.
    Forconi S; Pieragalli D; Acciavatti A; Del Bigo C; Galigani C; Ralli L; Guerrini M; Di Perri T
    J Int Med Res; 1984; 12(3):188-92. PubMed ID: 6734922
    [No Abstract]   [Full Text] [Related]  

  • 8. [Double-blind study of naftidrofuryl-hydrogen oxalate in peripheral arterial occlusive disease].
    Pohle W; Hirche H; Barmeyer J; Schümichen C; Hoffmann G
    Med Welt; 1979 Feb; 30(7):269-72. PubMed ID: 372733
    [No Abstract]   [Full Text] [Related]  

  • 9. [Buflomedil chlorhydrate in peripheral vasculopathies].
    Dall'Antonia F; Perbellini A; Adami CA; Dal Cortivo G; Bucci S
    Clin Ter; 1986 Dec; 119(5):379-85. PubMed ID: 2951055
    [No Abstract]   [Full Text] [Related]  

  • 10. A placebo-controlled study of the effects of intravenous Buflomedil on foot skin microcirculation in patients with severe intermittent claudication.
    Van den Brande P; Maurel A
    Angiology; 1998 Feb; 49(2):105-14. PubMed ID: 9482510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New data on vasoactive drug. Patients with peripheral arterial occlusive disease walk twice as long].
    MMW Fortschr Med; 2002 May; 144(21):54. PubMed ID: 12134429
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparison of 2 effective doses of Fludilat in peripheral vascular disorders in a double-blind trial].
    König FK
    Med Welt; 1973 Sep; 24(39):1490-2. PubMed ID: 4588974
    [No Abstract]   [Full Text] [Related]  

  • 13. [Bencyclane in stage II arterial occlusive disease. Results of a controlled study].
    Trübestein G; Trübestein R; Ludwig M
    Fortschr Med; 1989 Dec; 107(36):781-4. PubMed ID: 2695437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Naftidrofuryl in arterial occlusive disease. Controlled multicenter double-blind study with oral administration].
    Maass U; Amberger HG; Böhme H; Diehm C; Dimroth H; Heidrich H; Heinrich F; Hirche H; Mörl H; Müller-Bühl U
    Dtsch Med Wochenschr; 1984 May; 109(19):745-50. PubMed ID: 6373217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
    ; Leizorovicz A; Becker F
    Circulation; 2008 Feb; 117(6):816-22. PubMed ID: 18212283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buflomedil for intermittent claudication.
    De Backer TL; Vander Stichele RH; Bogaert MG
    Cochrane Database Syst Rev; 2001; (1):CD000988. PubMed ID: 11279700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication.
    Diamantopoulos EJ; Grigoriadou M; Ifanti G; Raptis SA
    Int Angiol; 2001 Dec; 20(4):337-44. PubMed ID: 11782701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pentoxifylline (Trental)--a new drug for the treatment of peripheral chronic occlusive arterial disease.
    Chopra HK; Chopra KL; Aggarwal KK; Parashar SK
    J Med; 1988; 19(2):89-107. PubMed ID: 3049876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of buflomedil perfusion on peripheral tissue oxygenation during transluminal angioplasty in patients with advanced arteriopathy of the lower limbs].
    Joffre F; Meites G; Rousseau H; Staffin C; Allaert FA; Pelat P
    Ann Radiol (Paris); 1994; 37(3):239-44. PubMed ID: 8092756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Buflomedil in the treatment of chronic peripheral arterial diseases. Case contribution].
    Visconti W; Grillo N
    Minerva Med; 1985 May; 76(19-20):945-53. PubMed ID: 3158842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.